© 2026 Aureon Bioscience
SLU-PP-322 5mg - Wholesale
Sale price
$60.00
Regular price
$120.00
Skip to product information
SLU-PP-322 5mg - Wholesale
Overview
SLU-PP-322 (also referred to in published literature as SLU-PP-332) is a synthetic small molecule and pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), nuclear receptors that regulate mitochondrial function, oxidative metabolism, and energy expenditure in metabolically active tissues including skeletal muscle, cardiac muscle, and adipose tissue. It is classified as an exercise mimetic compound and is currently investigational, with no FDA approval. Research has been conducted primarily at the University of Florida and Saint Louis University.
Mechanism of Action
SLU-PP-322 activates ERRα (with approximately 4-fold selectivity over ERRγ), triggering an acute aerobic exercise-like gene expression program. This activation upregulates genes involved in mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and skeletal muscle fiber type remodeling toward oxidative (Type IIa) fibers. The compound does not affect appetite, food intake, or hormonal axes.
Research Applications and Preclinical Findings
In diet-induced obese and ob/ob mouse models, twice-daily administration for 28 days resulted in approximately 12% reduction in body weight and significantly attenuated fat mass accumulation. Normal-weight mice demonstrated up to 70% improvement in exercise endurance and 45% increase in running distance. Additional preclinical research suggests cardioprotective effects including improved cardiac ejection fraction, reduced fibrosis, and normalized fatty acid oxidation in heart failure models. Potential applications are being explored in metabolic syndrome, obesity, sarcopenia, muscular dystrophy, and age-related metabolic decline.
Administration
Currently administered via subcutaneous injection in research settings. Oral formulation development is ongoing. Not FDA-approved; human trials have not yet been reported.
Potential Adverse Effects
No severe adverse effects reported in preclinical models to date. Potential mild effects include injection site irritation, fatigue, and headache. Long-term human safety data is absent.
Properties
1. Basic Information
2. Structural Properties Compound Nature: Synthetic small molecule containing a sulfonamide pharmacophore linked to a bicyclic aromatic scaffold; the structural design targets the ligand-binding domain of estrogen-related receptors (ERRα, ERRβ, ERRγ), which are constitutively active orphan nuclear receptors lacking endogenous ligands under basal conditions
Secondary Structure: N/A (small molecule); X-ray crystallographic and computational docking studies describe binding within the hydrophobic ligand-binding pocket of the ERR ligand-binding domain, inducing a conformation that stabilizes the activation helix (helix 12) in an active state
Hydrophobicity: Moderately lipophilic; the bicyclic aromatic core contributes to membrane permeability and nuclear receptor ligand-binding pocket compatibility; calculated logP consistent with nuclear receptor ligand design parameters (estimated logP ~3.5–4.5)
Charge: Neutral to mildly acidic at physiological pH; sulfonamide NH has pKa typically above 9; compound is effectively neutral under physiological conditions
3. Solubility
4. Stability Thermal Stability: Stable as a solid under standard laboratory conditions; protect from prolonged light exposure; DMSO stock solutions stable at −20°C
Metabolic Stability: Metabolic stability profile not fully characterized in published literature; sulfonamide-containing compounds generally demonstrate moderate to good metabolic stability; in vivo preclinical studies utilized twice-daily subcutaneous dosing, suggesting a relatively short effective half-life requiring frequent administration
Storage: Store as solid at −20°C protected from light and moisture; DMSO stock solutions stable at −20°C for up to 12 months; avoid repeated freeze-thaw cycles
5. Chemical Reactivity Sulfonamide group is chemically stable under physiological conditions; resistant to hydrolysis at neutral pH
No reactive electrophilic groups identified; mechanism of ERR activation is non-covalent ligand binding within the receptor ligand-binding domain
Aromatic system is stable under standard storage and handling conditions; protect from strong oxidants and UV radiation
No stereocenters reported in the primary structure; achiral molecule
Compatible with standard organic chemistry handling procedures; no special containment requirements beyond standard laboratory practice
6. Other Properties
- Name: SLU-PP-322 (also referenced as SLU-PP-332 in some publications)
- Type: Synthetic small molecule nuclear receptor pan-agonist (ERRα/β/γ)
- Length: N/A (small molecule)
- Sequence: N/A
- Molecular Weight: ~418.5 Da
- Formula: C₂₄H₂₂N₂O₅S
2. Structural Properties Compound Nature: Synthetic small molecule containing a sulfonamide pharmacophore linked to a bicyclic aromatic scaffold; the structural design targets the ligand-binding domain of estrogen-related receptors (ERRα, ERRβ, ERRγ), which are constitutively active orphan nuclear receptors lacking endogenous ligands under basal conditions
Secondary Structure: N/A (small molecule); X-ray crystallographic and computational docking studies describe binding within the hydrophobic ligand-binding pocket of the ERR ligand-binding domain, inducing a conformation that stabilizes the activation helix (helix 12) in an active state
Hydrophobicity: Moderately lipophilic; the bicyclic aromatic core contributes to membrane permeability and nuclear receptor ligand-binding pocket compatibility; calculated logP consistent with nuclear receptor ligand design parameters (estimated logP ~3.5–4.5)
Charge: Neutral to mildly acidic at physiological pH; sulfonamide NH has pKa typically above 9; compound is effectively neutral under physiological conditions
3. Solubility
- Moderately soluble in DMSO (≥10 mg/mL); limited aqueous solubility consistent with lipophilic nuclear receptor ligand profile
- DMSO stock solutions at 10–20 mM used in cell-based research; dilute to ≤0.1% DMSO final concentration in biological assays
- Supplied as solid powder; vehicle formulations using PEG400, Tween-80, or cyclodextrin complexation reported in preclinical in vivo dosing protocols
4. Stability Thermal Stability: Stable as a solid under standard laboratory conditions; protect from prolonged light exposure; DMSO stock solutions stable at −20°C
Metabolic Stability: Metabolic stability profile not fully characterized in published literature; sulfonamide-containing compounds generally demonstrate moderate to good metabolic stability; in vivo preclinical studies utilized twice-daily subcutaneous dosing, suggesting a relatively short effective half-life requiring frequent administration
Storage: Store as solid at −20°C protected from light and moisture; DMSO stock solutions stable at −20°C for up to 12 months; avoid repeated freeze-thaw cycles
5. Chemical Reactivity Sulfonamide group is chemically stable under physiological conditions; resistant to hydrolysis at neutral pH
No reactive electrophilic groups identified; mechanism of ERR activation is non-covalent ligand binding within the receptor ligand-binding domain
Aromatic system is stable under standard storage and handling conditions; protect from strong oxidants and UV radiation
No stereocenters reported in the primary structure; achiral molecule
Compatible with standard organic chemistry handling procedures; no special containment requirements beyond standard laboratory practice
6. Other Properties
- Pan-ERR agonist: Activates all three estrogen-related receptor subtypes (ERRα, ERRβ, ERRγ) with reported approximately 4-fold selectivity for ERRα over ERRγ; ERRα is the primary mediator of the exercise-mimetic transcriptional response reported in preclinical literature
- Exercise mimetic classification: Preclinical gene expression profiling studies report that SLU-PP-322 treatment produces transcriptional signatures overlapping with aerobic exercise-induced gene expression programs in skeletal and cardiac muscle tissue
- Preclinical metabolic data: Diet-induced obese mouse models treated with SLU-PP-322 demonstrated approximately 12% body weight reduction and attenuated fat mass accumulation in 28-day studies; normal-weight mice showed up to 70% improvement in treadmill endurance and 45% increase in running distance
- Cardiac research context: Preclinical heart failure models report improved cardiac ejection fraction, reduced fibrosis markers, and normalized fatty acid oxidation pathway gene expression following SLU-PP-322 administration
- Research stage: No registered human clinical trials as of available literature; all data from cell culture and rodent model studies; developed from research programs at Saint Louis University and the University of Florida
Description
SLU-PP-322 is a synthetic research compound and has been described in the scientific literature as a pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), nuclear receptors associated with mitochondrial function, oxidative metabolism, and energy expenditure regulation in metabolically active tissues. Publications referencing SLU-PP-322 discuss it in the context of nuclear receptor pharmacology, exercise-associated gene expression programs, and mitochondrial biogenesis signaling within experimental systems.
Reports involving SLU-PP-322 describe its receptor activation characteristics and associated downstream signaling properties under defined experimental conditions. Observations of ERRα-mediated gene expression patterns, oxidative phosphorylation pathway components, fatty acid oxidation signaling markers, and skeletal muscle fiber type remodeling indicators are limited to non-clinical research settings and are reported as descriptive findings within cellular and animal model studies.
All references to SLU-PP-322 are confined to mechanistic and observational research contexts and do not extend beyond laboratory-based investigation.
In the scientific literature, SLU-PP-322 has been referenced in non-clinical research involving nuclear receptor binding assays, gene expression profiling studies, and preclinical metabolic and cardiac animal models. These publications describe experimental contexts in which molecular interactions, transcriptional activation markers, and pathway-associated signaling components were observed and recorded.
Reported research contexts include examination of:
- ERRα, ERRβ, and ERRγ receptor activation dynamics and associated gene expression patterns in experimental models
- Mitochondrial biogenesis and oxidative phosphorylation pathway markers observed in skeletal and cardiac muscle research settings
- Fatty acid oxidation signaling components and metabolic flexibility indicators evaluated under experimental conditions
- Skeletal muscle fiber type remodeling markers toward oxidative phenotype assessed in preclinical animal contexts
- Cardioprotective signaling pathway components including ejection fraction-associated markers and fibrosis indicators reported in heart failure models
All reported applications are confined to descriptive investigation within controlled laboratory research environments.
Mechanistic discussions in preclinical publications describe SLU-PP-322 as a small molecule ERR pan-agonist in which preferential activation of ERRα (reported at approximately 4-fold selectivity over ERRγ) is described as initiating an aerobic exercise-associated transcriptional program. This activation pattern is discussed in the context of exercise mimetic pharmacology within the cited literature. These descriptions are limited to molecular and biochemical observations within experimental systems and do not imply functional outcomes beyond the reported research context.
SLU-PP-322 is supplied as a research-grade compound material. Identity and composition have been reported as characterized using analytical techniques commonly applied to small molecule research materials, including chromatographic and mass spectrometric methods. Individual laboratories determine handling, storage, and analytical verification parameters in accordance with internal research protocols.
COA
Storage
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months. Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
